An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease

NCT07298590 | Not Yet Recruiting Early Phase 1

• 2 other identifiers: CHEC2025-364CHEC2025-473
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.

Conditions

IgG4 Related Disease

Outcome Measures

Primary Outcomes (3)

• Incidence of Dose-Limiting Toxicity (DLT)

  To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

  up to 48 weeks

• Incidence of Treatment Emergent Adverse Events (TEAEs)

  To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

  up to 48 weeks

• The percentage of disease remission (Remission is defined as IgG4-RD RI=0 after treatment and without the use of hormones

  To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

  24 weeks

Secondary Outcomes (10)

• Percentage of disease remission of IgG4-RD RI score compared with baseline

  12, 24, 48 weeks

• Percentage of complete response, partial response, and no change (NC)

  12, 24, 48 weeks

• Disease recurrence rate

  24, 48 weeks after infusion

• Physician Global Assessment (PhGA) compared with baseline

  up to 48 weeks

• Patient Global Assessment (PGA) compared with baseline

  12, 24, 48 weeks

Study Arms (1)

This study is a single-arm, open-label and single-center exploratory clinical study

EXPERIMENTAL

Biological: CD19/BCMA CAR NK

Interventions

CD19/BCMA CAR NK BIOLOGICAL

Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of CD19/BCMA CAR NK cells will infused using the dose-escalation strategy.

This study is a single-arm, open-label and single-center exploratory clinical study

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be able to understand and provide informed consent and be willing to comply with study procedures and follow-up.
• The age at the time of signing the informed consent must be at least 18 years old and no more than 70 years old.
• Meet the 2020 Japanese criteria or ACR/EULAR IgG4-RD classification criteria.
• Subjects with relapsed/refractory active IgG4-RD at screening on an IgG4-RD RI ≥4, simultaneously meeting the following definitions of relapse or refractory disease:
• Definitions of relapse: subjects with IgG4-RD achieved remission after treatment but was active again before screening, and were classified as a high-risk group for recurrence assessed by assessment committee ;
• Definitions of before screening: subjects had used glucocorticoids or glucocorticoids combined with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) (including cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, elorimod, thalidomide, etc.), or at least one approved biologic agent (bDMARDs) (including rituximab, abatacept, etanercept, belimumab, etc.), or targeted synthetic (ts) DMARDs (including tofacitinib, upadacitinib, baricitinib, abrocitinib, deucravacitinib, etc.) for treatment, with a total treatment duration of ≥3 months, yet still in an active disease state, ineffective, intolerant, or experiencing relapse during glucocorticoid tapering.
• No history of severe allergic reaction.
• Female participants of childbearing age must have a negative pregnancy test upon enrollment in the study; indeterminate results will not be accepted.
• Female subjects of childbearing age and male subjects with female partners of childbearing potential must agree to consistently use effective methods of birth control within 6 months after the last KN5601 infusion.
• Echocardiography show that the heart structure is basically normal and the left ventricular ejection fraction (LVEF) is ≥55%; no obvious abnormalities are found on the electrocardiogram.
• Pulmonary function: No severe lung disease, SpO2 ≥ 92%.
• All subjects' eligibility for enrollment must be confirmed by an independent Assessment Committee (AC) (the committee consists of independent data monitors and clinical experts separate from the study). They will review the eligibility of each patient based on the scores entered at screening, as well as brief descriptions provided by the investigators regarding the supporting diagnosis, scores, and the patient's clinical status in relation to enrollment criteria..

You may not qualify if:

• Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic Glucocorticoids (GC) for disease control during the period of the trial.
• Malignancy within 5 years (except successfully treated in situ cancer, resected squamous cell or basal cell carcinoma of the skin.).
• During the screening visit, one of the following laboratory test values must be met, except for those caused by IgG4-RD.:
• Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times the upper limit of normal (ULN).
• Total bilirubin \> two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin \> three times ULN.
• White blood cell (WBC) count \<3.0×10⁹/L;
• Absolute neutrophil count (ANC) \<1.5×10⁹/L;
• Hemoglobin \<90 g/L;
• Platelet count \<75×10⁹/L;
• Estimated glomerular filtration rate (eGFR) ≤ 45 ml/(min·1.73m2).
• Evidence suggests the presence of another uncontrolled disease, which the investigator has determined may affect the subject's participation in the trial.
• Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization.
• Received rituximab or other B-cell depleting therapies within 6 months prior to the baseline visit, unless B cells have recovered (B-cell recovery is defined as peripheral blood B-cell count ≥ the lower limit of normal reference range or returned to pre-treatment levels)。
• The use of supplemental oxygen at baseline.
• During the screening visit or within 90 days prior to the screening visit: T-SPOT positive. If the result is indeterminate, the T-SPOT must be repeated (using the same or a different T-SPOT) and shown as negative.

Sponsors & Collaborators

• Changhai Hospital: lead

Study Sites (1)

Changhai Hospital

Shanghai, 200433, China

Location

MeSH Terms

Conditions

Immunoglobulin G4-Related Disease

Condition Hierarchy (Ancestors)

Autoimmune Diseases; Immune System Diseases

Study Officials

• Zhuan Liao

  Changhai Hospital

  STUDY CHAIR

Central Study Contacts

Lei Xin

CONTACT

086-13817318134; aip_xin@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: December 23, 2025
• Study Start: December 30, 2025
• Primary Completion (Estimated): June 26, 2028
• Study Completion (Estimated): December 26, 2028
• Last Updated: December 23, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)